Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Centene Corporation reported a fourth quarter 2025 adjusted diluted loss per share of $1.19, leading to a full-year adjusted diluted EPS of $2.08, slightly exceeding prior expectations despite a challenging year.</li><li>The company highlighted improvements in Medicaid profitability, a key business segment, with a fourth quarter health benefits ratio (HBR) improving to 93.0%, reflecting sequential progress from earlier quarters.</li><li>Medicaid guidance anticipates stable margins in 2026, supported by a composite rate increase of approximately 5.5% above 2024 levels and a net trend expectation around the mid-4% range.</li></ul>

Centene Corporation reported a fourth quarter 2025 adjusted diluted loss per share of $1.19, leading to a full-year adjusted diluted EPS of $2.08, slightly exceeding prior expectations despite a challenging year.The company highlighted improvements in Medicaid profitability, a key business segment, with a fourth quarter health benefits ratio (HBR) improving to 93.0%, reflecting sequential progress from earlier quarters.Medicaid guidance anticipates stable margins in 2026, supported by a composite rate increase of approximately 5.5% above 2024 levels and a net trend expectation around the mid-4% range.

Centene Corporation’s Medicaid Reset Is Working—Here’s What’s Quietly Driving Margin Stability!

Cross-Asset Strategist & Quantitative Analyst, Pennock Idea Hub

Cam Hui

Cross-Asset Strategist & Quantitative Analyst

Pennock Idea Hub

We are creators of independent equity research. The Pennock Idea Hub team are veterans of the investment industry. Much of our team has spent their careers at Merrill Lynch, Deutsche Bank, RBC Capital Markets and Wood Gundy. We have taken every aspect of research back to the studs and returned to first principles. The Pennock Idea Hub marries the interests of the sell and buy side. 

We offer the best research for institutional investors by:

-Only publishing research from veteran analysts
-Eliminate the inherent conflicts of the traditional sell and buy side relationship
-Ensure our team is always accessible; collaboration with clients nurtures our collective success

Cross-Asset & Quantitative Research

Cross Asset Strategy

<ul>
<li>The stock market is likely to advance during the Santa Claus rally window, which began on December 24 and ends January 3.</li>
<li>But the rally is attributed to an oversold bounce and marked by narrow leadership. Either the rebound fizzles in January or broadens into lagging issues.</li>
<li>We identified selected contrarian value opportunities for bulls among Santa’s discards for potential outperformance into January and beyond.</li>
</ul>


The stock market is likely to advance during the Santa Claus rally window, which began on December 24 and ends January 3.
But the rally is attributed to an oversold bounce and marked by narrow leadership. Either the rebound fizzles in January or broadens into lagging issues.
We identified selected contrarian value opportunities for bulls among Santa’s discards for potential outperformance into January and beyond.


Contrarian Bargains Among Santa's Discards

External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Key points (machine generated)<ul><li>CNC has withdrawn financial guidance due to a $1.8 billion shortfall from the Affordable Care Act and rising Medicaid costs, causing stock price to drop to $32.</li><li>Market perception indicates a permanent earnings impairment at 4.5 times the projected adjusted EPS of $7.17 for 2024, but EPS could rebound to at least $7.06 in 18 to 24 months.</li><li>CNC, the largest managed care organization for U.S. government-sponsored health insurance, serves 27.9 million members and has shifted its capital allocation strategy towards share repurchases since 2022.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)CNC has withdrawn financial guidance due to a $1.8 billion shortfall from the Affordable Care Act and rising Medicaid costs, causing stock price to drop to $32.Market perception indicates a permanent earnings impairment at 4.5 times the projected adjusted EPS of $7.17 for 2024, but EPS could rebound to at least $7.06 in 18 to 24 months.CNC, the largest managed care organization for U.S. government-sponsored health insurance, serves 27.9 million members and has shifted its capital allocation strategy towards share repurchases since 2022.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Centene Corp (CNC) - Monday, Jul 14, 2025

Smartkarma's AI Co-Pilot, Smartkarma

αSK

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
 <li>
<a href="https://smartkarma.com/entities/centene-corp-98c57d0c-2f86-4b86-8163-44d4377b59a0">Centene </a>is the largest Medicaid managed care organization in the United States, with a significant presence in Medicare and the Health Insurance Marketplace, making it a key player in government-sponsored healthcare.</li>
 <li>The company is currently navigating significant headwinds, including pressures from the Medicaid redetermination process, rising medical costs, and regulatory uncertainties, which have led to increased investor concern and a withdrawal of its 2025 guidance.</li>
 <li>Management is focused on a value creation plan that involves divesting non-core assets to improve profitability, expanding its geographic footprint in Medicaid, and leveraging technology to enhance operational efficiency and care management.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Centene is the largest Medicaid managed care organization in the United States, with a significant presence in Medicare and the Health Insurance Marketplace, making it a key player in government-sponsored healthcare.
  The company is currently navigating significant headwinds, including pressures from the Medicaid redetermination process, rising medical costs, and regulatory uncertainties, which have led to increased investor concern and a withdrawal of its 2025 guidance.
  Management is focused on a value creation plan that involves divesting non-core assets to improve profitability, expanding its geographic footprint in Medicaid, and leveraging technology to enhance operational efficiency and care management.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

<ul><li>Centene Corporation recently reported its financial outcomes for the first quarter of 2025, detailing both its present achievements and future expectations.</li><li>The highlights of their performance reveal a complex interplay of growth prospects and operational challenges within the different segments it operates.</li><li>For the first quarter, Centene achieved an adjusted diluted EPS of $2.90, aligning with prior forecasts.</li></ul>

Centene Corporation recently reported its financial outcomes for the first quarter of 2025, detailing both its present achievements and future expectations.The highlights of their performance reveal a complex interplay of growth prospects and operational challenges within the different segments it operates.For the first quarter, Centene achieved an adjusted diluted EPS of $2.90, aligning with prior forecasts.

Centene Corporation: Leveraging Clinical Initiatives & Operating Models To Change The Game!

United States

Centene Corporation provides multi-line healthcare solutions to individuals across all states and internationally. Centene's specialty services include medicaid and medicare health plans, treatment compliance, and nurse triage.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Centene (CNC UN)

Centene Corporation’s Medicaid Reset Is Working—Here’s What’s Quietly Driving Margin Stability!

Centene Corporation reported a fourth quarter 2025 adjusted diluted loss per share of $1.19, leading to a full-year adjusted diluted EPS of $2.08,...

Baptista Research

Contrarian Bargains Among Santa's Discards

We identified selected contrarian value opportunities for bulls among Santa’s discards for potential outperformance into January and beyond.

Cam Hui

Centene Corp (CNC) - Monday, Jul 14, 2025

CNC has withdrawn financial guidance due to a $1.8 billion shortfall, causing its stock to drop to $32, but EPS may rebound to $7.06 in 18-24...

Value Investors Club (VIC)

Primer: Centene (CNC UN) - Sep 2025

Centene is the largest Medicaid managed care organization in the United States, with a significant presence in Medicare and the Health...

αSK

Centene Corporation: Leveraging Clinical Initiatives & Operating Models To Change The Game!

Centene Corporation recently reported its financial outcomes for the first quarter of 2025, detailing both its present achievements and future...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)